Baris Akinci

AD autosomal dominant AGPAT2 1-acylglycerol-3-phosphate O-acyltransferase 2 AIRE autoimmune regulator ANA antinuclear antibodies AR autosomal recessive AT adipose tissue B supportive biological evidence BANF1 barrier to autointegration nuclear assembly factor 1 BSCL2 lipid droplet biogenesis associated, seipin C3/4 complement component 3/4 CAV1 caveolin 1 CIDEC cell death inducing DFFA like effector c ClinGen clinical genome dsDNA double-stranded deoxyribonucleic acid DXA dual energy x-ray...

Highlights Some patients with nonalcoholic steatohepatitis have relatively low leptin levels In this subgroup, leptin therapy leads to reduced hepatic fat and lower NASH scores Similar improvements are observed in a group of subjects with partial lipodystrophy The therapeutic benefit of leptin may go beyond severe leptin deficiency Context and significance Fat goes to the liver when the body has limited fat storage capacity, damaging liver cells.

Previous article in Early View: Addition of a dipeptidyl peptidase-4 inhibitor, sitagliptin, to ongoing therapy with the glucagon-like peptide-1 receptor agonist liraglutide: A randomized controlled trial in patients with type 2 diabetes Previous article in Early View: Addition of a dipeptidyl peptidase-4 inhibitor, sitagliptin, to ongoing therapy with the glucagon-like peptide-1 receptor agonist liraglutide: A randomized controlled trial in patients with type 2 diabetes Next article in Early...